�A drug widely put-upon to care for
high cholesterol is serving beat cancer. Lovastatin is part of a modern cancer
treatment that has arrested or eradicated tumors in more than 80% of
initial patients. The first mortal treated with the investigatory protocol
in 2000 had stage 4 melanoma; he remains disease-free today.
Lovastatin, the number one of the statin mathematical group of lipoid fighters, was
introduced in 1980. Early studies revealed an unexpected side effect ---
killing or impairing cancer cells in laboratory cultures. Excitement among
cancer researchers subsided, however, when it appeared that world could
not tolerate the levels required to move tumors significantly. While some
researchers ar reconsidering the usefulness of statins to treat malignant neoplastic disease,
one Nashville physician already is eyesight its success against some of the
most lethal malignancies.
According to NeoPlas Innovation Director of Research Dr. Stephen
Cantrell, "The key to moving beyond theory to success and survival in real
patients has been finding the right practice of medicine to combine with mevacor.
When we have administered a on the nose timed regime of low-dose interferon
with lovastatin, tumors have begun regressing, sometimes within just a few
weeks."
So far each NeoPlas melanoma patient has experienced results
significantly better than those with standard therapy. Eradication of
tumors or long-term stability has occurred in most patients. Others give birth
seen a substantial retardation of progression.
Staff members expect the best results for several malignancies based on
go through and relevant lab research to date. In addition to melanoma,
these admit pancreatic genus Cancer, colon cancer, renal (kidney) cancer,
mesothelioma, and a group of sarcomas, including osteosarcoma,
chondrosarcoma and malignant fibrous histiocytoma. The regimen is non
expected to have pregnant benefit against brain tumors.
The most notable side effect is fatigue. Most patients ne'er experience
side effects ordinarily affiliated with chemotherapy or radiation (nausea,
vomiting, haircloth loss, ivory marrow suppression or immune system inhibition).
An experienced physician prescribes and monitors the outpatient treatment
and maintains close communication with the patient's established
oncologist. Patients are not ineligible because of previous treatments.
NeoPlas Innovation
http://www.neoplas.org
More info
